公开(公告)号：US20240002512A1

公开(公告)日：2024-01-04

申请号：US18052076

申请日：2022-11-02

Applicant: Bristol-Myers Squibb Company

Inventor： John P. COGSWELL ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574

CPC classification number: C07K16/2818 ,  C07K16/2827 ,  A61K39/3955 ,  C07K16/18 ,  C07K16/2803 ,  G01N33/57492 ,  A61K2039/505

Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

公开(公告)号：US10604575B2

公开(公告)日：2020-03-31

申请号：US16231211

申请日：2018-12-21

Applicant: Bristol-Myers Squibb Company

Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

公开(公告)号：US10577423B2

公开(公告)日：2020-03-03

申请号：US16248222

申请日：2019-01-15

Applicant: Bristol-Myers Squibb Company

Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

公开(公告)号：US20190382491A1

公开(公告)日：2019-12-19

申请号：US16529230

申请日：2019-08-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Maria Jure-Kunkel ,  David M. Berman ,  Alan J. Korman ,  Mark J. Selby ,  Suba Krishnan

IPC: C07K16/28 ,  C07K16/30

Abstract: This disclosure provides a method for treating a subject afflicted with a cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to PD-1; and (b) an antibody or an antigen-binding portion thereof that specifically binds to CD 137.

公开(公告)号：US10266596B1

公开(公告)日：2019-04-23

申请号：US16213965

申请日：2018-12-07

Applicant: Bristol-Myers Squibb Company

Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/574 ,  C07K16/18 ,  A61K39/00

Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

公开(公告)号：US20190112376A1

公开(公告)日：2019-04-18

申请号：US16230657

申请日：2018-12-21

Applicant: Bristol-Myers Squibb Company

Inventor： John P. COGSWELL ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574

Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

公开(公告)号：US10100129B2

公开(公告)日：2018-10-16

申请号：US15520638

申请日：2015-11-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nils Lonberg ,  Alan J. Korman ,  Bryan C. Barnhart ,  Aaron P. Yamniuk ,  Mohan Srinivasan ,  Karla A. Henning ,  Ming Lei ,  Emanuela Sega ,  Angela Goodenough ,  Maria Jure-Kunkel ,  Guodong Chen ,  John S. Sack ,  Richard Y. Huang ,  Martin J. Corbett ,  Joseph E. Myers, Jr. ,  Liang Schweizer ,  Sandra V. Hatcher ,  Haichun Huang ,  Pingping Zhang

IPC: A61K39/00 ,  C07K16/40 ,  C07K16/28 ,  A61K47/68 ,  C07K16/30 ,  A61K39/395 ,  A61K45/06 ,  G01N33/574

Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.

公开(公告)号：US10072082B2

公开(公告)日：2018-09-11

申请号：US14950748

申请日：2015-11-24

Applicant: Bristol-Myers Squibb Company

Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/53 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/76 ,  G01N33/57492 ,  G01N2333/70596 ,  G01N2800/52 ,  Y02A50/41 ,  Y02A50/412

Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

公开(公告)号：US09856320B2

公开(公告)日：2018-01-02

申请号：US14400667

申请日：2013-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok Kumar Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/76 ,  G01N33/57492 ,  G01N2333/70596 ,  G01N2800/52 ,  Y02A50/41 ,  Y02A50/412

Abstract: The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

公开(公告)号：US20140193422A1

公开(公告)日：2014-07-10

申请号：US14211438

申请日：2014-03-14

Applicant: Bristol-Myers Squibb Company

Inventor： Maria Jure-Kunkel ,  Laura J. Hefta ,  Marc Santoro ,  Subinay Ganguly ,  Edward L. Halk

IPC: C07K16/30

CPC classification number: C07K16/2878 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/55516 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92 ,  C12N2740/15034 ,  A61K2300/00

Abstract: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.

Abstract translation: 与人4-1BB结合并允许人4-1BB与人4-1BB配体结合的完全人抗体及其抗原结合部分。 一方面，抗体是IgG4抗体。 还提供了治疗受试者疾病的方法，包括向所述受试者施用治疗有效量的抗体。